Li Dan, Zeng Zhi, Yu Tao, Qin Jian, Wu Jie, Song Jin-Chun, Zhou Zi-Ying, Yuan Jing-Ping
Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
Department of Pathology, Renmin Hospital of Wuhan University, No 238, Jiefang Road, Wuchang District, Wuhan, 430060, Hubei, People's Republic of China.
Tumour Biol. 2016 May;37(5):6551-9. doi: 10.1007/s13277-015-4460-5. Epub 2015 Dec 5.
S100 protein family has been implicated in multiple stages of tumorigenesis and progression in which S100A12 is one of the subtypes. However, the role of S100A12 in gastric carcinoma (GC) has not been elucidated yet. This study was aimed to investigate the expression of S100A12 in GC tissues and evaluate the clinical significance of S100A12 in GC patients. S100A12 protein was detected in 207 GC and 52 paired non-cancerous mucosal tissues by immunohistochemistry, while messenger RNA (mRNA) was investigated by Oncomine database analysis. Moreover, survival analysis was performed and the correlation between S100A12 and ubiquitin-specific protease 10 (USP10) and p53 was determined. As for tumor cells, the expression of S100A12 protein and mRNA in GC was proved to be lower than that in non-cancerous mucosa tissues (p < 0.05). Clinicopathological analysis showed that S100A12 protein was negatively associated with tumor size (p = 0.004), depth of invasion (p = 0.022), tumor node metastasis (TNM) stage (p = 0.018), Lauren classification (p < 0.000), and cell differentiation (p < 0.000). In contrast, a positive correlation was found between S100A12 and USP10 protein (p < 0.000). However, no relationship was detected between S100A12 and p53. Moreover, the survival analysis indicated that S100A12 protein was a favorable factor of prognosis of GC (p < 0.05). Although the expression of S100A12 in the stromal cells was detected higher than that in the tumor cells, no relationship between S100A12 protein in stromal cells and the clinicopathological features described above was found (p > 0.05). Our findings suggested that low expression of S100A12 might be served as a new marker in the tumorigenesis and progression of GC.
S100蛋白家族与肿瘤发生和发展的多个阶段有关，其中S100A12是亚型之一。然而，S100A12在胃癌（GC）中的作用尚未阐明。本研究旨在探讨S100A12在GC组织中的表达，并评估S100A12在GC患者中的临床意义。通过免疫组织化学检测207例GC组织和52例配对的非癌黏膜组织中的S100A12蛋白，同时通过Oncomine数据库分析研究信使核糖核酸（mRNA）。此外，进行生存分析，并确定S100A12与泛素特异性蛋白酶10（USP10）和p53之间的相关性。对于肿瘤细胞，GC中S100A12蛋白和mRNA的表达被证明低于非癌黏膜组织（p<0.05）。临床病理分析表明，S100A12蛋白与肿瘤大小（p=0.004）、浸润深度（p=0.022）、肿瘤淋巴结转移（TNM）分期（p=0.018）、Lauren分类（p<0.000）和细胞分化（p<0.000）呈负相关。相反，发现S100A12与USP10蛋白呈正相关（p<0.000）。然而，未检测到S100A12与p53之间的关系。此外，生存分析表明，S100A12蛋白是GC预后的有利因素（p<0.05）。虽然检测到基质细胞中S100A12的表达高于肿瘤细胞，但未发现基质细胞中S100A12蛋白与上述临床病理特征之间的关系（p>0.05）。我们的研究结果表明，S100A12的低表达可能作为GC发生和发展的一个新标志物。
